Tanja Obradovich: This month marks Keytruda reaching 40 approved indications in the US

Tanja Obradovich shared on LinkedIn:

“This month (as of June 17th) marks Keytruda reaching 40 approved indications in the US.

FDA just approved Keytruda in combination with Carboplatin and Paclitaxel, followed by Keytruda monotherapy for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.

Huge congrats on this amazing milestone to Merck Women’s Cancer Center Clinical team and superb leader Gursel Aktan on bringing new frontline treatment to patients across mismatch repair spectrum who have endometrial tumors either proficient (pMMR) or with mismatch repair deficient (dMMR) status.”

Additional information.
Source: Tanja Obradovich/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.